[go: up one dir, main page]

WO2014079464A1 - Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih) - Google Patents

Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih) Download PDF

Info

Publication number
WO2014079464A1
WO2014079464A1 PCT/EG2012/000033 EG2012000033W WO2014079464A1 WO 2014079464 A1 WO2014079464 A1 WO 2014079464A1 EG 2012000033 W EG2012000033 W EG 2012000033W WO 2014079464 A1 WO2014079464 A1 WO 2014079464A1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
reverse transcriptase
pharmaceutical compositions
enzyme
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EG2012/000033
Other languages
English (en)
Inventor
Sherif Salah Abdul Aziz
Nada Sherif Salah ABDUL AZIZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/EG2012/000033 priority Critical patent/WO2014079464A1/fr
Publication of WO2014079464A1 publication Critical patent/WO2014079464A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • HIV Human Immunodeficiency Virus
  • This invention relates to a novel inhibitors for retroviral protease, More particularly, the invention is concerned with formation of immune antibodies against the viral enzymes of human immunodeficiency virus (HIV) .As such this antibodies have potential use for the treatment of acquired immune deficiency virus syndrome and other retroviruses
  • HIV human immunodeficiency virus
  • This invention relates to a novel inhibitors for retroviral protease, More particularly, the invention is concerned with formation of immune antibodies against the viral enzymes of human immunodeficiency virus (HIV) .As such this antibodies have potential use for the treatment of acquired immune deficiency virus syndrome and other retroviruses
  • HIV human immunodeficiency virus
  • HIV human immunodeficiency vims
  • AIDS acquired immunodeficiency syndrome
  • the instant invention discuses die causes of susceptibility to infection with HIV
  • DNA polymerase enzyme is the main enzyme for processes of viral replication and producing new viron.
  • the invention depend on how we can induce our immune cells to produce antibodies against some enzymes compatible with our system 5-
  • This invention stimulates the immune cells to stin ting in formation by voluntary mechanism the switch off antibodies which protect our immune cell from over consuming.
  • the instant invention introduced novel DNA polymerase inhibitors which can enhance the effect of anticancer drugs and antiviral drugs.
  • Plate 1-1 explain the mechanism of HIV pathophysiology and process of treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne l'utilisation d'enzymes bifonctionnelles pour présenter des anticorps de neutralisation à spectre extrêmement large, les rendant ainsi un agent antiviral potentiel efficace contre le virus de l'immunodéficience humaine (VIH).
PCT/EG2012/000033 2012-11-21 2012-11-21 Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih) Ceased WO2014079464A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EG2012/000033 WO2014079464A1 (fr) 2012-11-21 2012-11-21 Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EG2012/000033 WO2014079464A1 (fr) 2012-11-21 2012-11-21 Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)

Publications (1)

Publication Number Publication Date
WO2014079464A1 true WO2014079464A1 (fr) 2014-05-30

Family

ID=47388475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2012/000033 Ceased WO2014079464A1 (fr) 2012-11-21 2012-11-21 Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)

Country Status (1)

Country Link
WO (1) WO2014079464A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004105A1 (fr) * 1995-07-14 1997-02-06 University Of Washington Adn-polymerase de virus d'herpes gamma associes a la maladie de kaposi et a la fibromatose retroperitoneale
WO2000061766A2 (fr) * 1999-04-09 2000-10-19 Biomira, Inc. Vaccin anticancereux specifique de la telomerase
WO2002070679A2 (fr) * 2001-03-02 2002-09-12 Gemvax As Vaccins
US20040247613A1 (en) * 1997-04-18 2004-12-09 Geron Corporation Treating cancer using a telomerase vaccine
US20080175861A1 (en) * 2006-12-22 2008-07-24 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004105A1 (fr) * 1995-07-14 1997-02-06 University Of Washington Adn-polymerase de virus d'herpes gamma associes a la maladie de kaposi et a la fibromatose retroperitoneale
US20040247613A1 (en) * 1997-04-18 2004-12-09 Geron Corporation Treating cancer using a telomerase vaccine
WO2000061766A2 (fr) * 1999-04-09 2000-10-19 Biomira, Inc. Vaccin anticancereux specifique de la telomerase
WO2002070679A2 (fr) * 2001-03-02 2002-09-12 Gemvax As Vaccins
US20080175861A1 (en) * 2006-12-22 2008-07-24 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIBA J ET AL: "Generation of neutralizing antibody to the reverse transcriptase of human immunodeficiency virus type 1 by immunizing of mice with an infectious vaccinia virus recombinant", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 207, no. 1, 22 August 1997 (1997-08-22), pages 53 - 60, XP027447300, ISSN: 0022-1759, [retrieved on 19970822], DOI: 10.1016/S0022-1759(97)00104-X *
KLUTCH M ET AL: "Generation of HIV-1/HIV-2 cross-reactive peptide antisera by small sequence changes in HIV-1 reverse transcriptase and integrase immunizing peptides.", 1998, JOURNAL OF BIOMEDICAL SCIENCE 1998, VOL. 5, NR. 3, PAGE(S) 192 - 202, ISSN: 1021-7770, XP009171614 *

Similar Documents

Publication Publication Date Title
Kumar et al. The macrophage: a therapeutic target in HIV-1 infection
Hamill et al. Novel anti-infectives: is host defence the answer?
Bobbin et al. RNA interference approaches for treatment of HIV-1 infection
EP2216028B1 (fr) Stimulation immunitaire au moyen de RNA monocaténaire modifié chimiquement
Khalid et al. HIV and messenger RNA (mRNA) vaccine
US20230310594A1 (en) Methods of treating a latent hiv-1 infection using non-coding deoxyribonucleic acids
WO2008154482A3 (fr) Compositions d'arnsi et procédés d'utilisation dans le traitement de maladies oculaires
JP2019520061A5 (fr)
Saifullah et al. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
SG170825A1 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2014079464A1 (fr) Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)
ATE486088T1 (de) Hiv-impfstoff
RU2007115549A (ru) Вакцины на основе инактивированного цельного вируса совместимого субтипа для лечения пациентов с вич-инфекцией
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
KR101426996B1 (ko) 테트라케라 스캔덴스 에탄올 추출물을 유효성분으로 포함하는 항바이러스 조성물 및 이의 용도
RU2765589C9 (ru) Способ лечения вич
Parmar et al. Novel targets: host proteins, nucleic acid, and antibodies
CN102727523A (zh) 一种具有抗hiv潜伏作用的药物及其用途
WO2004066954A3 (fr) Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2
Höglund Natural killer cells and solid tumours: New therapies ahead?
JP2022151441A (ja) 筋炎と筋膜炎の治療薬。
Dwivedi et al. Anti-HIV therapy: pipeline approaches and future directions
Ts'o The major advances in scientific research which currently have a significant impact on medicine can be generally described in two areas: 1) application of instrumentation such as laser beam surgery and NMR imaging, etc. and 2) the understanding of biology and medicine at the
Stanley Jeremiah et al. Cancellers-Exploring the Possibility of Receptor Decoy Traps as a Superior Anti-Retroviral Strategy
KR20070050934A (ko) Ｔ-세포 조절에 의한 ｈｉｖ 감염의 치료 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12803504

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12803504

Country of ref document: EP

Kind code of ref document: A1